Research News for June 2011
11–20 of 20 articles
-
Adding Tykerb to Herceptin and Chemo Improves Survival in Metastatic, HER2-Positive Disease
Research suggests that treating women diagnosed with metastatic, HER2-positive breast cancer with Tykerb and Herceptin and chemotherapy improves survival compared to only Herceptin and chemotherapy.
-
Nexavar May Help Treat Some Metastatic Breast Cancers
Research suggests that some women diagnosed with advanced-stage breast cancer benefit more from chemotherapy and Nexavar compared to chemotherapy and placebo (a sugar pill).
-
Tykerb and Xeloda Can Help Treat Breast Cancer That’s Spread to the Brain
A small, early study found that treating women diagnosed with metastatic, HER2-positive breast cancer that has spread to the brain with a combination of Tykerb and Xeloda can shrink the cancer in some women.
-
Flaxseed Doesn’t Seem to Ease Hot Flashes
Research shows that flaxseed doesn't ease hot flashes.
-
New Medicines That Slow Cancer’s Growth Don’t Seem to Improve Survival
Research shows no link between progression-free survival and overall survival in experimental breast cancer treatment trials.
-
Lymph Node Radiation Therapy Lowers Risk of Metastatic Recurrence
Research suggests that women with a higher-than-average risk of recurrence were less likely to have a recurrence if they got whole breast radiation AND lymph node radiation instead of just whole breast radiation.
-
Aromasin Helps Reduce Breast Cancer Risk in High-Risk Women
Research shows that the hormonal therapy Aromasin can lower risk in high-risk, postmenopausal women who've never been diagnosed with breast cancer.
-
High C-Reactive Protein Levels May Influence Prognosis
Research suggests that C-reactive protein levels may be linked to prognosis after a breast cancer diagnosis.
-
FDA Says Thermography Shouldn’t Be Substituted for Mammograms
The FDA has warned that thermography should not be substituted for mammography.
-
Zometa Plus Hormonal Therapy Reduces Recurrence Risk
A study has found that Zometa and hormonal therapy after surgery could reduce the risk of the cancer coming back in premenopausal women diagnosed with early-stage, hormone-receptor-positive breast cancer better than hormonal therapy alone.
11–20 of 20 articles
